Literature DB >> 30484930

Analysis of 17 948 pediatric patients undergoing procedural sedation with a combination of intranasal dexmedetomidine and ketamine.

Fei Yang1, Yang Liu1,2,3, Qing Yu1,2,3, Shangyingying Li1, Jin Zhang1, Mang Sun1, Lu Liu1, Yao Lei1, Qing Tian1, Hui Liu1, Shengfen Tu1.   

Abstract

BACKGROUND: Intranasal procedural sedation using dexmedetomidine is well described in the literature. The combination of intranasal dexmedetomidine and ketamine is a novel approach for which there are little data on the rate of successful sedation or adverse events.
OBJECTIVES: The aim of this study is to evaluate the rate of successful sedation and adverse events of intranasal procedural sedation using a combination of dexmedetomidine and ketamine for diagnostic examination in children.
METHODS: This was a retrospective study and data were collected after ethics approval. A total of 17 948 pediatric patients (7718 females, 10 230 males) in a tertiary hospital in China were evaluated. Patients received a combination of 2 μg kg-1 of dexmedetomidine and 1 mg kg-1 of ketamine intranasally for procedural sedation. The level of sedation and recovery was assessed by the Modified Observer Assessment of Alertness/Sedation scale and the Modified Aldrete Score.
RESULTS: The rate of intranasal sedation success was 93% (16691/17948), intranasal sedation rescue was 1.8% (322/17948), and intranasal sedation failure was 5.2% (935/17948). Sedation success was defined as successful completed the diagnostic examination and obtained adequate diagnostic-quality images and reports. Intranasal sedation success, rescue and failure were respectively defined as sedation success with intranasal a single dose, additional bolus dose and the need for intravenous (IV) medications/inhalation agents. Median sedation time was 62 min (interquartile range: 55-70 min), median time for onset of sedation was 15 min (interquartile range: 15-20 min), and median sedation recovery time was 45 min (interquartile range: 38-53 min). Incidence of adverse events was low (0.58%; 105/17948), with major and minor adverse event being reported in 0.02% (4/17948) and 0.56% (101/17948) patients, respectively. Postoperative nausea and vomiting was the most common (0.3%; 53/17948) minor adverse event.
CONCLUSION: Procedural sedation using a combination of intranasal dexmedetomidine and ketamine is associated with acceptable effectiveness and low rates of adverse events.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  adverse events; dexmedetomidine and ketamine; intranasal

Mesh:

Substances:

Year:  2018        PMID: 30484930     DOI: 10.1111/pan.13526

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  9 in total

1.  Analysis of Risk Factors for Chloral Hydrate Sedative Failure with Initial Dose in Pediatric Patients: a Retrospective Analysis.

Authors:  Yu Cui; Langtao Guo; Qixia Mu; Lu Kang; Qin Chen; Qunying Wu; Yani He; Min Tang
Journal:  Paediatr Drugs       Date:  2022-05-21       Impact factor: 3.022

2.  Comparative evaluation of nebulized ketamine and its combination with dexmedetomidine as premedication for paediatric patients undergoing surgeries under general anaesthesia.

Authors:  Shital A Dharamkhele; Shalendra Singh; M S Honwad; Venkata Krishna Gollapalli; Nipun Gupta
Journal:  Med J Armed Forces India       Date:  2021-02-23

3.  Intranasal dexmedetomidine and intravenous ketamine for procedural sedation in a child with alpha-mannosidosis: a magic bullet?

Authors:  Matteo Trevisan; Sara Romano; Egidio Barbi; Irene Bruno; Flora Maria Murru; Giorgio Cozzi
Journal:  Ital J Pediatr       Date:  2019-09-03       Impact factor: 2.638

4.  The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis.

Authors:  Rui Du; Ruili Han; Kun Niu; Jiaqiao Xu; Zihou Zhao; Guofang Lu; Yulong Shang
Journal:  Front Psychiatry       Date:  2022-03-09       Impact factor: 4.157

5.  A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial.

Authors:  Xinlei Lu; Ling Tang; Haiyan Lan; Chunli Li; Han Lin
Journal:  Front Pharmacol       Date:  2022-01-27       Impact factor: 5.810

6.  Using intranasal dexmedetomidine with buccal midazolam for magnetic resonance imaging sedation in children: A single-arm prospective interventional study.

Authors:  Bi Lian Li; Hao Luo; Jun Xiang Huang; Huan Huan Zhang; Joanna R Paquin; Vivian M Yuen; Xing Rong Song
Journal:  Front Pediatr       Date:  2022-08-04       Impact factor: 3.569

7.  Ketamine Enhances Intranasal Dexmedetomidine-Induced Sedation in Children: A Randomized, Double-Blind Trial.

Authors:  Bin Qian; Wenting Zheng; Jiawei Shi; Zihan Chen; Yanhua Guo; Yusheng Yao
Journal:  Drug Des Devel Ther       Date:  2020-08-26       Impact factor: 4.162

8.  Intranasal dexmedetomidine is an effective sedative agent for electroencephalography in children.

Authors:  Hang Chen; Fei Yang; Mao Ye; Hui Liu; Jing Zhang; Qin Tian; Ruiqi Liu; Qing Yu; Shangyingying Li; Shengfen Tu
Journal:  BMC Anesthesiol       Date:  2020-03-07       Impact factor: 2.217

9.  Off-label use of dexmedetomidine in paediatric anaesthesiology: an international survey of 791 (paediatric) anaesthesiologists.

Authors:  Camille E van Hoorn; Robert B Flint; Justin Skowno; Paul Davies; Thomas Engelhardt; Kirk Lalwani; Olutoyin Olutoye; Erwin Ista; Jurgen C de Graaff
Journal:  Eur J Clin Pharmacol       Date:  2020-10-29       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.